Cargando…

Lung function trajectories in patients with idiopathic pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function. We evaluated trajectories of forced vital capacity (FVC) and diffusing capacity (DLco) in a cohort of patients with IPF. METHODS: Patients with IPF that was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neely, Megan L, Hellkamp, Anne S, Bender, Shaun, Todd, Jamie L, Liesching, Timothy, Luckhardt, Tracy R, Oldham, Justin M, Raj, Rishi, White, Eric S, Palmer, Scott M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463468/ https://www.ncbi.nlm.nih.gov/pubmed/37612608 http://dx.doi.org/10.1186/s12931-023-02503-5

Ejemplares similares

Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry
por: Swaminathan, Aparna C., et al.
Publicado: (2022)

Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry
por: Case, Amy Hajari, et al.
Publicado: (2020)

Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression
por: Ruan, Peifeng, et al.
Publicado: (2023)

Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry
por: Kim, Hyun J., et al.
Publicado: (2022)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

Hospitalizations in patients with idiopathic pulmonary fibrosis
por: Kim, Hyun J., et al.
Publicado: (2021)

Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry
por: Snyder, Laurie, et al.
Publicado: (2019)

Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
por: de Andrade, Joao A., et al.
Publicado: (2022)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis
por: Gulati, Swati, et al.
Publicado: (2020)

A retrospective study of in-hospital mortality in patients with idiopathic pulmonary fibrosis between 2015 and 2018
por: Durheim, Michael T., et al.
Publicado: (2020)

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
por: Oldham, Justin M., et al.
Publicado: (2017)

On Target: CYFRA 21-1 as an Idiopathic Pulmonary Fibrosis Biomarker
por: Spagnolo, Paolo, et al.
Publicado: (2022)

Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
por: Todd, Jamie L., et al.
Publicado: (2020)

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
por: Todd, Jamie L., et al.
Publicado: (2019)

Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
por: Todd, Jamie L., et al.
Publicado: (2022)

Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients
por: Kulkarni, Tejaswini, et al.
Publicado: (2019)

Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
por: Todd, Jamie L., et al.
Publicado: (2022)

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021)

In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis: A US Cohort Study
por: Durheim, Michael T., et al.
Publicado: (2019)

Evaluating the consistency with guideline recommendations for diagnosis and management of idiopathic pulmonary fibrosis in non-academic settings
por: Luckhardt, Tracy R., et al.
Publicado: (2023)

Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
por: Amati, Francesco, et al.
Publicado: (2022)

Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
por: Astor, Todd L., et al.
Publicado: (2023)

In-hospital mortality trends among patients with idiopathic pulmonary fibrosis in the United States between 2013-2017: a comparison of academic and non-academic programs
por: Alqalyoobi, Shehabaldin, et al.
Publicado: (2020)

T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival
por: Bonham, Catherine A., et al.
Publicado: (2019)

A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis
por: Huang, Yong, et al.
Publicado: (2015)

Airway soluble CSF1R predicts progression in patients with idiopathic pulmonary fibrosis
por: Oldham, Justin M., et al.
Publicado: (2023)

Novel idiopathic pulmonary fibrosis susceptibility variants revealed by deep sequencing
por: Lorenzo-Salazar, Jose M., et al.
Publicado: (2019)

Proportion of Idiopathic Pulmonary Fibrosis Risk Explained by Known Common Genetic Loci in European Populations
por: Leavy, Olivia C., et al.
Publicado: (2021)

Canine acquired pneumonia caused by Bordetella bronchiseptica
por: Tatem, Luis Lantigua, et al.
Publicado: (2023)

Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
por: Zhang, David, et al.
Publicado: (2023)

Genome-wide Enrichment of TERT Rare Variants in Idiopathic Pulmonary Fibrosis Patients of Latino Ancestry
por: Zhang, David, et al.
Publicado: (2022)

PCSK6 and Survival in Idiopathic Pulmonary Fibrosis
por: Oldham, Justin M., et al.
Publicado: (2023)

Latent Class Trajectory and Growth Mixture Models in the Study of Physical Resilience
por: Pieper, Carl, et al.
Publicado: (2020)

Cellular Senescence in Idiopathic Pulmonary Fibrosis
por: Kellogg, D. L., et al.
Publicado: (2021)

Differentiation of Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Related Interstitial Lung Disease Using Quantitative Imaging
por: Chung, Jonathan H., et al.
Publicado: (2021)

Using group based trajectory modeling for assessing medication adherence to nintedanib among idiopathic pulmonary fibrosis patients
por: Nili, Mona, et al.
Publicado: (2023)

Cough in Idiopathic Pulmonary Fibrosis
por: Mann, Jennifer, et al.
Publicado: (2021)

The effect of a tiered provider staffing model on patient outcomes during the coronavirus disease 2019 pandemic: A single-center observational study
por: Dargin, James, et al.
Publicado: (2021)

Pulmonologists' Perspectives on and Access to Palliative Care for Patients With Idiopathic Pulmonary Fibrosis in South Carolina
por: Lindell, Kathleen Oare, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kot31a2m597pbtac2qnc0ll8ae